---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-276691"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-06-22T11:08:42+00:00"
generated_at: "2026-06-22T11:10:32.089477+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MapLight's ML-004 Phase 2 misses primary endpoint in autism; shows signal in adolescent irritability

## Summary
- Primary endpoint (ABI-Social Communication) not met in Phase 2 IRIS trial of ML-004 in ASD.
- Adolescents with baseline ABC-I≥16 showed improvement (ES=1.33, p=0.013) on ABC-I and CGI-I irritability (ES=1.08, p=0.036).
- ML-004 well-tolerated; no severe/serious AEs in active arm, no extrapyramidal events, weight gain lower than placebo.
- Company to engage FDA for End-of-Phase 2 meeting; Phase 2 ZEPHYR (schizophrenia) topline due mid-Aug 2026.

## SEC filing metadata
- accession: 0001193125-26-276691
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-06-22T11:08:42+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/0001193125-26-276691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/d31456d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-276691
- JSON: https://secwatch.observer/filing/0001193125-26-276691.json
- Plain text: https://secwatch.observer/filing/0001193125-26-276691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.